Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects

Next Previous
Trial Profile

A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs R 835 Rigel Pharmaceuticals (Primary)
  • Indications Arthritis; Gout; Immunological disorders; Multiple sclerosis; Psoriasis
  • Focus Adverse reactions

    • Most Recent Events

    • 23 Oct 2019 Status changed from recruiting to completed, according to a Rigel Pharmaceuticals media release.
    • 06 Aug 2019 According to a Rigel Pharmaceuticals media release, data from this study is expected in the second half of 2019.
    • 02 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top